A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip.

Autor:	Sengupta A; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland., Dorn A; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland.; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Jamshidi M; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland., Schwob M; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland., Hassan W; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland., De Maddalena LL; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Hugi A; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Stucki AO; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland., Dorn P; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.; Department for BioMedical Research, University of Bern, Bern, Switzerland., Marti TM; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.; Department for BioMedical Research, University of Bern, Bern, Switzerland., Wisser O; VITROCELL Systems GmbH, Waldkirch, Germany., Stucki JD; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Krebs T; VITROCELL Systems GmbH, Waldkirch, Germany., Hobi N; AlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland., Guenat OT; Organs-on-Chip Technologies, ARTORG Center for Biomedical Engineering, University of Bern, Bern, Switzerland.; Department of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.; Department of Pulmonary Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2023 Mar 06; Vol. 14, pp. 1114739. Date of Electronic Publication: 2023 Mar 06 (Print Publication: 2023).
DOI:	10.3389/fphar.2023.1114739
Abstrakt:	Prolonged exposure to environmental respirable toxicants can lead to the development and worsening of severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and fibrosis. The limited number of FDA-approved inhaled drugs for these serious lung conditions has led to a shift from in vivo towards the use of alternative in vitro human-relevant models to better predict the toxicity of inhaled particles in preclinical research. While there are several inhalation exposure models for the upper airways, the fragile and dynamic nature of the alveolar microenvironment has limited the development of reproducible exposure models for the distal lung. Here, we present a mechanistic approach using a new generation of exposure systems, the Cloud α AX12. This novel in vitro inhalation tool consists of a cloud-based exposure chamber (VITROCELL) that integrates the breathing AX Lung-on-chip system (AlveoliX). The ultrathin and porous membrane of the AX12 plate was used to create a complex multicellular model that enables key physiological culture conditions: the air-liquid interface (ALI) and the three-dimensional cyclic stretch (CS). Human-relevant cellular models were established for a) the distal alveolar-capillary interface using primary cell-derived immortalized alveolar epithelial cells ( AX iAECs), macrophages (THP-1) and endothelial (HLMVEC) cells, and b) the upper-airways using Calu3 cells. Primary human alveolar epithelial cells ( AX hAEpCs) were used to validate the toxicity results obtained from the immortalized cell lines. To mimic in vivo relevant aerosol exposures with the Cloud α AX12, three different models were established using: a) titanium dioxide (TiO2) and zinc oxide nanoparticles b) polyhexamethylene guanidine a toxic chemical and c) an anti-inflammatory inhaled corticosteroid, fluticasone propionate (FL). Our results suggest an important synergistic effect on the air-blood barrier sensitivity, cytotoxicity and inflammation, when air-liquid interface and cyclic stretch culture conditions are combined. To the best of our knowledge, this is the first time that an in vitro inhalation exposure system for the distal lung has been described with a breathing lung-on-chip technology. The Cloud α AX12 model thus represents a state-of-the-art pre-clinical tool to study inhalation toxicity risks, drug safety and efficacy. Competing Interests: OG, NH, and JS hold equity in AlveoliX AG. LM, AH, NH, and JS are employed by AlveoliX. OW and TK are employed by VITROCELL Systems GmbH. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Sengupta, Dorn, Jamshidi, Schwob, Hassan, De Maddalena, Hugi, Stucki, Dorn, Marti, Wisser, Stucki, Krebs, Hobi and Guenat.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu